SCM
VIR icon

Stonepine Capital Management’s Vir Biotechnology VIR Stock Holding History

Stonepine Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-160,000
Closed -$914K – 85
2025
Q3 		$914K Buy
160,000
+30,000
+23% +$153K 0.74% 30
2025
Q2 		$655K Sell
130,000
-14,628
-10% -$78.4K 0.64% 36
2025
Q1 		$937K Sell
144,628
-19,478
-12% -$173K 0.91% 23
2024
Q4 		$1.2M Buy
+164,106
New +$1.29M 0.97% 26

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Stonepine Capital Management's VIR Position: Q4 2025 in Review

Stonepine Capital Management sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 160,000 shares — an estimated $914K sold.

Stonepine Capital Management first reported a position in VIR in Q4 2024 and held it in 4 quarters. The position peaked at $1.2M in Q4 2024. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • Stonepine Capital Management reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 160,000 Vir Biotechnology shares in Q4 2025, an estimated $914K.
  • Stonepine Capital Management first reported a position in Vir Biotechnology in Q4 2024 and held it in 4 quarters.
  • Stonepine Capital Management's Vir Biotechnology position peaked at $1.2M in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.